全文获取类型
收费全文 | 17868篇 |
免费 | 1322篇 |
国内免费 | 500篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 684篇 |
妇产科学 | 570篇 |
基础医学 | 1151篇 |
口腔科学 | 88篇 |
临床医学 | 1723篇 |
内科学 | 6865篇 |
皮肤病学 | 88篇 |
神经病学 | 437篇 |
特种医学 | 212篇 |
外国民族医学 | 1篇 |
外科学 | 626篇 |
综合类 | 2680篇 |
预防医学 | 1000篇 |
眼科学 | 64篇 |
药学 | 2332篇 |
8篇 | |
中国医学 | 919篇 |
肿瘤学 | 232篇 |
出版年
2023年 | 216篇 |
2022年 | 204篇 |
2021年 | 453篇 |
2020年 | 491篇 |
2019年 | 485篇 |
2018年 | 517篇 |
2017年 | 550篇 |
2016年 | 562篇 |
2015年 | 545篇 |
2014年 | 937篇 |
2013年 | 1488篇 |
2012年 | 1008篇 |
2011年 | 1079篇 |
2010年 | 853篇 |
2009年 | 850篇 |
2008年 | 941篇 |
2007年 | 901篇 |
2006年 | 749篇 |
2005年 | 641篇 |
2004年 | 648篇 |
2003年 | 600篇 |
2002年 | 451篇 |
2001年 | 419篇 |
2000年 | 386篇 |
1999年 | 321篇 |
1998年 | 247篇 |
1997年 | 254篇 |
1996年 | 192篇 |
1995年 | 179篇 |
1994年 | 176篇 |
1993年 | 157篇 |
1992年 | 151篇 |
1991年 | 138篇 |
1990年 | 99篇 |
1989年 | 115篇 |
1988年 | 118篇 |
1987年 | 113篇 |
1986年 | 105篇 |
1985年 | 140篇 |
1984年 | 131篇 |
1983年 | 71篇 |
1982年 | 115篇 |
1981年 | 106篇 |
1980年 | 122篇 |
1979年 | 103篇 |
1978年 | 80篇 |
1977年 | 73篇 |
1976年 | 64篇 |
1973年 | 63篇 |
1970年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
1.
2.
3.
4.
《Value in health》2022,25(7):1235-1252
ObjectivesThe incidence of type 1 diabetes mellitus is increasing every year requiring substantial expenditure on treatment and complications. A systematic review was conducted on the cost-effectiveness of insulin formulations, including ultralong-, long-, or intermediate-acting insulin, and their biosimilar insulin equivalents.MethodsMEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, HTA, and NHS EED were searched from inception to June 11, 2021. Cost-effectiveness and cost-utility analyses were included if insulin formulations in adults (≥ 16 years) with type 1 diabetes mellitus were evaluated. Two reviewers independently screened titles, abstracts, and full-text articles, extracted study data, and appraised their quality using the Drummond 10-item checklist. Costs were converted to 2020 US dollars adjusting for inflation and purchasing power parity across currencies.ResultsA total of 27 studies were included. Incremental cost-effectiveness ratios ranged widely across the studies. All pairwise comparisons (11 of 11, 100%) found that ultralong-acting insulin was cost-effective compared with other long-acting insulins, including a long-acting biosimilar. Most pairwise comparisons (24 of 27, 89%) concluded that long-acting insulin was cost-effective compared with intermediate-acting insulin. Few studies compared long-acting insulins with one another.ConclusionsLong-acting insulin may be cost-effective compared with intermediate-acting insulin. Future studies should directly compare biosimilar options and long-acting insulin options and evaluate the long-term consequences of ultralong-acting insulins. 相似文献
5.
Marc Evans MD Susanne Engberg MD Mads Faurby MSc João Diogo Da Rocha Fernandes MSc Pollyanna Hudson MSc William Polonsky PhD 《Diabetes, obesity & metabolism》2022,24(3):377-390
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety-two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%-84.3%]) or persistent (median [range] 47.7% [16.9%-94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget-neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes. 相似文献
6.
7.
8.
通过回顾分析我院2例确诊为胰岛素自身免疫综合征(IAS)患者的临床资料,并复习相关文献,总结发病机制及治疗方法,探讨IAS患者的临床特点,提高对低血糖症的诊治水平。 相似文献
9.